quinacrine has been researched along with Disease Models, Animal in 33 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 7.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 3.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| " For this, extended subacute ovalbumin mice model of asthma was developed; these mice showed an increased expression of profibrotic mediators, subepithelial fibrosis, and goblet cell metaplasia along with airway inflammation, increased Th(2) cytokines, allergen-specific IgE, IgG(1), increased cytosolic PLA(2) (cPLA(2)), and airway hyperresponsiveness." | 3.75 | Mepacrine inhibits subepithelial fibrosis by reducing the expression of arginase and TGF-beta1 in an extended subacute mouse model of allergic asthma. ( Agrawal, A; Aich, J; Ghosh, B; Mabalirajan, U, 2009) |
| "Renal toxicity is a serious side effect that hinders the use of cisplatin, a commonly used and effective chemotherapeutic agent." | 1.62 | Quinacrine Ameliorates Cisplatin-Induced Renal Toxicity via Modulation of Sirtuin-1 Pathway. ( Abo El-Magd, NF; Ebrahim, HA; Eisa, NH; El-Sherbiny, M, 2021) |
| "Quinacrine was then administered to adult 5XFAD transgenic mice via weekly intravenous injections for 6 weeks, and we found a significant reduction of Aβ plaques and astrocytosis in their cortex and hippocampus." | 1.62 | Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer's disease. ( Kim, HY; Kim, Y; Oh, HA; Park, IW; Park, S; Shin, J; Woo, DH; Yoon, S, 2021) |
| "Using the stasis model of venous thrombosis and resolution in mice, we found that genetic deficiency of p53 or pharmacologic inhibition by pifithrin impairs thrombus resolution and is associated with increased fibrosis and altered expression of matrix metalloproteinase-2." | 1.46 | Myeloid p53 regulates macrophage polarization and venous thrombus resolution by inflammatory vascular remodeling in mice. ( Antalis, TM; Hoofnagle, MH; Mukhopadhyay, S; Nguyen, KP; Sarkar, R, 2017) |
| "Quinacrine is an anti-malarial drug with versatile use in the treatment of diseases involving inflammatory response such as rheumatoid arthritis and lupus erythematosus." | 1.43 | Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties. ( Chaparala, A; Chumanevich, A; Chumanevich, AA; Hofseth, LJ; Nagarkatti, M; Nagarkatti, P; Witalison, EE, 2016) |
| "Quinacrine is a relatively non-toxic drug, once given almost exclusively for malaria." | 1.42 | Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP). ( Blum, AB; Donahue, MJ; Fisher, DT; Haslinger, ML; Kim, M; Park, IY; Skitzki, JJ, 2015) |
| " However, animals dosed with human equivalent doses of quinacrine were not protected against respiratory spore challenge." | 1.33 | Evaluation of the protective effects of quinacrine against Bacillus anthracis Ames. ( Chatuev, BM; Chopra, AK; Comer, JE; McHenry, DJ; Noffsinger, DM; Peterson, JW; Weisbaum, DM, 2006) |
| "Quinacrine was demonstrated to penetrate rapidly into brain tissue, achieving concentrations up to 1500 ng/g, which is several-fold greater than that demonstrated to inhibit formation of PrPSc in cell culture." | 1.32 | Pharmacokinetics of quinacrine in the treatment of prion disease. ( Baldwin, M; Guglielmo, BJ; Huang, Y; Legname, G; Lessard, P; Lin, ET; Prusiner, SB; Ryou, C; Yung, L, 2004) |
| "Peritonitis has been produced in rabbits by the spreading of 5 ml of caecal contents throughout the peritoneal cavity." | 1.27 | A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits. ( Bennett, ED; Hynd, J; Moss, R; Parker-Williams, J; Tighe, D, 1987) |
| "In the Piebald mouse, animal model of congenital megacolon, the quinacrine positive plexus is thin in the distal narrowed segment and well developed in the large proximal zone." | 1.26 | [Colonic nerve network demonstrated by quinacrine]. ( Adnet, JJ; Arnaudies, J; Birembaut, P; Gaillard, D; Ploton, D; Visseaux-Coletto, B, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.09) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, CR | 1 |
| Chen, X | 1 |
| Shi, L | 1 |
| Liu, JO | 1 |
| Sullivan, DJ | 1 |
| Dodean, RA | 1 |
| Kancharla, P | 1 |
| Li, Y | 1 |
| Melendez, V | 1 |
| Read, L | 1 |
| Bane, CE | 1 |
| Vesely, B | 1 |
| Kreishman-Deitrick, M | 1 |
| Black, C | 1 |
| Li, Q | 1 |
| Sciotti, RJ | 1 |
| Olmeda, R | 1 |
| Luong, TL | 1 |
| Gaona, H | 1 |
| Potter, B | 1 |
| Sousa, J | 1 |
| Marcsisin, S | 1 |
| Caridha, D | 1 |
| Xie, L | 1 |
| Vuong, C | 1 |
| Zeng, Q | 1 |
| Zhang, J | 1 |
| Zhang, P | 1 |
| Lin, H | 1 |
| Butler, K | 1 |
| Roncal, N | 1 |
| Gaynor-Ohnstad, L | 1 |
| Leed, SE | 1 |
| Nolan, C | 1 |
| Huezo, SJ | 1 |
| Rasmussen, SA | 1 |
| Stephens, MT | 1 |
| Tan, JC | 1 |
| Cooper, RA | 1 |
| Smilkstein, MJ | 1 |
| Pou, S | 1 |
| Winter, RW | 1 |
| Riscoe, MK | 1 |
| Kelly, JX | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Abo El-Magd, NF | 1 |
| Ebrahim, HA | 1 |
| El-Sherbiny, M | 1 |
| Eisa, NH | 1 |
| Kim, HG | 1 |
| Kim, CW | 1 |
| Lee, DH | 1 |
| Lee, JS | 1 |
| Oh, ET | 1 |
| Park, HJ | 1 |
| Park, S | 1 |
| Kim, HY | 1 |
| Oh, HA | 1 |
| Shin, J | 1 |
| Park, IW | 1 |
| Yoon, S | 1 |
| Woo, DH | 1 |
| Kim, Y | 1 |
| Mukhopadhyay, S | 2 |
| Antalis, TM | 1 |
| Nguyen, KP | 1 |
| Hoofnagle, MH | 1 |
| Sarkar, R | 2 |
| Zhu, S | 1 |
| Chen, Z | 1 |
| Wang, L | 1 |
| Peng, D | 1 |
| Belkhiri, A | 1 |
| Lockhart, AC | 1 |
| El-Rifai, W | 1 |
| Pfaff, MJ | 1 |
| Hoofnagle, M | 1 |
| Chabasse, C | 1 |
| Xiong, Z | 1 |
| Zhang, K | 1 |
| Ishima, T | 1 |
| Ren, Q | 1 |
| Ma, M | 1 |
| Pu, Y | 1 |
| Chang, L | 1 |
| Chen, J | 1 |
| Hashimoto, K | 1 |
| Navarro, MA | 1 |
| Shrestha, A | 1 |
| Freedman, JC | 1 |
| Beingesser, J | 1 |
| McClane, BA | 1 |
| Uzal, FA | 1 |
| Lane, TR | 1 |
| Comer, JE | 2 |
| Freiberg, AN | 1 |
| Madrid, PB | 1 |
| Ekins, S | 1 |
| Spata, T | 1 |
| Bobek, D | 1 |
| Whitson, BA | 1 |
| Parthasarathy, S | 1 |
| Mohler, PJ | 1 |
| Higgins, RS | 1 |
| Kilic, A | 1 |
| Kim, M | 1 |
| Blum, AB | 1 |
| Haslinger, ML | 1 |
| Donahue, MJ | 1 |
| Fisher, DT | 1 |
| Skitzki, JJ | 1 |
| Park, IY | 1 |
| Chumanevich, AA | 1 |
| Witalison, EE | 1 |
| Chaparala, A | 1 |
| Chumanevich, A | 1 |
| Nagarkatti, P | 1 |
| Nagarkatti, M | 1 |
| Hofseth, LJ | 1 |
| Teruya, K | 1 |
| Doh-Ura, K | 1 |
| Spilman, P | 1 |
| Lessard, P | 2 |
| Sattavat, M | 1 |
| Bush, C | 1 |
| Tousseyn, T | 1 |
| Huang, EJ | 1 |
| Giles, K | 1 |
| Golde, T | 1 |
| Das, P | 1 |
| Fauq, A | 1 |
| Prusiner, SB | 2 |
| Dearmond, SJ | 2 |
| Yoo, S | 1 |
| Han, S | 1 |
| Park, YS | 1 |
| Lee, JH | 1 |
| Oh, U | 1 |
| Hwang, SW | 1 |
| Mabalirajan, U | 3 |
| Aich, J | 1 |
| Agrawal, A | 2 |
| Ghosh, B | 3 |
| Ahmad, T | 1 |
| Hasija, K | 1 |
| Bajsarowicz, K | 1 |
| Ahn, M | 1 |
| Ackerman, L | 1 |
| Dearmond, BN | 1 |
| Carlson, G | 1 |
| Fuchigami, T | 1 |
| Kobashi, N | 1 |
| Haratake, M | 1 |
| Kawasaki, M | 1 |
| Nakayama, M | 1 |
| Collins, SJ | 1 |
| Lewis, V | 1 |
| Brazier, M | 1 |
| Hill, AF | 1 |
| Fletcher, A | 1 |
| Masters, CL | 1 |
| Yung, L | 1 |
| Huang, Y | 1 |
| Legname, G | 1 |
| Lin, ET | 1 |
| Baldwin, M | 1 |
| Ryou, C | 1 |
| Guglielmo, BJ | 1 |
| Noffsinger, DM | 1 |
| McHenry, DJ | 1 |
| Weisbaum, DM | 1 |
| Chatuev, BM | 1 |
| Chopra, AK | 1 |
| Peterson, JW | 1 |
| Lima, AA | 1 |
| Nascimento, NR | 1 |
| Fang, GD | 1 |
| Yotseff, P | 1 |
| Toyama, MH | 1 |
| Guerrant, RL | 1 |
| Fonteles, MC | 1 |
| Kang, JJ | 1 |
| Toma, I | 1 |
| Sipos, A | 1 |
| Meer, EJ | 1 |
| Vargas, SL | 1 |
| Peti-Peterdi, J | 1 |
| Ram, A | 1 |
| Singh, SK | 1 |
| Singh, VP | 1 |
| Gaillard, D | 1 |
| Birembaut, P | 1 |
| Ploton, D | 1 |
| Arnaudies, J | 1 |
| Visseaux-Coletto, B | 1 |
| Adnet, JJ | 1 |
| Zipper, J | 1 |
| Dabancens, A | 1 |
| Guerrero, A | 1 |
| Trujillo, V | 1 |
| Reddington, M | 1 |
| Novak, EK | 1 |
| Hurley, E | 1 |
| Medda, C | 1 |
| McGarry, MP | 1 |
| Swank, RT | 1 |
| Tighe, D | 1 |
| Moss, R | 1 |
| Parker-Williams, J | 1 |
| Hynd, J | 1 |
| Bennett, ED | 1 |
2 reviews available for quinacrine and Disease Models, Animal
| Article | Year |
|---|---|
Insights from Therapeutic Studies for PrP Prion Disease.
Topics: Aminopyridines; Animals; Creutzfeldt-Jakob Syndrome; Disease Models, Animal; Doxycycline; Drug Disco | 2017 |
Quinacrine: sclerosing agent of the utero-tubal junction in women, with anticarcinogenic actions in transplanted tumors in mice.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans | 1995 |
31 other studies available for quinacrine and Disease Models, Animal
| Article | Year |
|---|---|
A clinical drug library screen identifies astemizole as an antimalarial agent.
Topics: Animals; Antimalarials; Astemizole; Chloroquine; Disease Models, Animal; Dose-Response Relationship, | 2006 |
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
Topics: Acridones; Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Hep G2 Cells; Humans; Mal | 2019 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Quinacrine Ameliorates Cisplatin-Induced Renal Toxicity via Modulation of Sirtuin-1 Pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Disease Models, Animal; Fibrosis; Immunohistoc | 2021 |
Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; | 2019 |
Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Humans; Mice; Mice, Trans | 2021 |
Myeloid p53 regulates macrophage polarization and venous thrombus resolution by inflammatory vascular remodeling in mice.
Topics: Animals; Disease Models, Animal; Fibrosis; Gene Expression Regulation, Enzymologic; Macrophages; Mat | 2017 |
A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; | 2018 |
Tumor suppressor protein p53 negatively regulates ischemia-induced angiogenesis and arteriogenesis.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Benzothiazoles; Blood Flow Velocity; | 2018 |
Lack of rapid antidepressant effects of Kir4.1 channel inhibitors in a chronic social defeat stress model: Comparison with (R)-ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Disease Models, A | 2019 |
Potential Therapeutic Effects of Mepacrine against
Topics: Animals; Anti-Bacterial Agents; Caco-2 Cells; Clostridium Infections; Clostridium perfringens; Disea | 2019 |
Repurposing Quinacrine against Ebola Virus Infection
Topics: Animals; Antimalarials; Antiviral Agents; Caco-2 Cells; Chlorocebus aethiops; Disease Models, Animal | 2019 |
A nonthoracotomy myocardial infarction model in an ovine using autologous platelets.
Topics: Animals; Coloring Agents; Coronary Vessels; Disease Models, Animal; Male; Microscopy, Fluorescence; | 2013 |
Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP).
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Extremities; Female; Melanoma, Experimental; | 2015 |
Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties.
Topics: Animals; Antimalarials; Cell Line; Colitis, Ulcerative; Colon; Cyclooxygenase 2; Dextran Sulfate; Di | 2016 |
A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains.
Topics: Administration, Oral; Alanine; Amyloid Precursor Protein Secretases; Animals; Azepines; Brain; Dendr | 2008 |
Lipoxygenase inhibitors suppressed carrageenan-induced Fos-expression and inflammatory pain responses in the rat.
Topics: Animals; Carrageenan; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regu | 2009 |
Mepacrine inhibits subepithelial fibrosis by reducing the expression of arginase and TGF-beta1 in an extended subacute mouse model of allergic asthma.
Topics: Animals; Arginase; Asthma; Bronchial Hyperreactivity; Disease Models, Animal; Epithelial Cells; Fibr | 2009 |
Mepacrine treatment attenuates allergic airway remodeling segregated from airway inflammation in mice.
Topics: Airway Remodeling; Animals; Anti-Asthmatic Agents; Arginase; Asthma; Blotting, Western; Collagen; Cy | 2011 |
A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.
Topics: Alanine; Animals; Azepines; Brain; Cathepsin D; Dendrites; Disease Models, Animal; Embryo, Mammalian | 2012 |
Synthesis and biological evaluation of radioiodinated quinacrine-based derivatives for SPECT imaging of Aβ plaques.
Topics: Acridines; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Female; Iodine Radioisotop | 2013 |
Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.
Topics: Animals; Creutzfeldt-Jakob Syndrome; Disease Models, Animal; Enzyme Inhibitors; Female; Mice; Mice, | 2002 |
Pharmacokinetics of quinacrine in the treatment of prion disease.
Topics: Administration, Oral; Animals; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; | 2004 |
Evaluation of the protective effects of quinacrine against Bacillus anthracis Ames.
Topics: Administration, Intranasal; Animals; Anthrax; Bacillus anthracis; Bioterrorism; Disease Models, Anim | 2006 |
Role of phospholipase A2 and tyrosine kinase in Clostridium difficile toxin A-induced disruption of epithelial integrity, histologic inflammatory damage and intestinal secretion.
Topics: Animals; Bacterial Toxins; Cell Line, Tumor; Disease Models, Animal; Drug Combinations; Enterotoxins | 2008 |
The collecting duct is the major source of prorenin in diabetes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Division; Cells, Cultured; Di | 2008 |
Mepacrine alleviates airway hyperresponsiveness and airway inflammation in a mouse model of asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Bro | 2008 |
[Colonic nerve network demonstrated by quinacrine].
Topics: Adenosine Triphosphatases; Animals; Colon; Disease Models, Animal; Hirschsprung Disease; Humans; Mic | 1982 |
Immature dense granules in platelets from mice with platelet storage pool disease.
Topics: Animals; Blood Platelet Disorders; Blood Platelets; Cytoplasmic Granules; Disease Models, Animal; Fe | 1987 |
A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits.
Topics: Animals; Disease Models, Animal; Lung; Microscopy, Electron; Peritonitis; Phospholipases; Quinacrine | 1987 |